The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.
Do you have a website? Looking for the best hosting provider? Here’s a discount code.
Latest Public Health Jobs
Latest Posts
- National Action Plan on Antimicrobial Resistance (2024-2028)
- IRS Guideline for Kala-zar and Malaria 2081
- INclusive, Sustainable, Prosperous and REsilient (INSPIRE) Health Systems in Asia and the Pacific Health Forum
- South-East Asia Physical Activity Conference 2025 (SEAPAC 2025)
- International Day of Yoga 2025: Yoga for One Earth, One Health
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at blog.publichealthupdate@gmail.com.
#StayUpdated
